Ethel Weld, MD

Protocol chair, IMPAACT 2005
Protocol vice-chair, IMPAACT 2022
Member, Clinical Pharmacology Advisory Group of the ACTG Laboratory Steering Committee (2018-Present)
Member, ACTG Antiretroviral Therapy Strategies Transformative Science Group Less Frequent Dosing ART Working Group
Member, Pharmacology Core, HPTN Laboratory Core
Member, TB in Pregnancy Working Group
Protocol pharmacologist for HPTN 086, IMPAACT CAP 544, IMPAACT CAP 543

We will address our hypothesis using a case-control study design. We plan to leverage the existing biorepository of...

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....

1077BF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

IMPAACT 2010 is a Phase III, three-arm, randomized, open-label study of HIV-1-infected pregnant women initiating either a...

A5361s is a prospective study to determine the effects of pitavastatin on physical function. The study will enroll participants...

Johns Hopkins University Baltimore-India Clinical Trials Unit